Entourage Health Corp. (OTCQX: ETRGF) (TSX-V:ENTG) (FSE:4WE) Q3 2022 net revenue was $10.1 million, a decrease of 7.0% year-over-year from $10.7 million in Q3 2021.

Q3 2022 Financial Highlights

Supply Agreement with HEXO Corp.

Entourage executed a long-term cannabis supply agreement with HEXO Corp. (NASDAQ: HEXO) (TSX:HEXO) Under the agreement, HEXO will provide bulk biomass and soft gel capsules to be marketed to patients and consumers under Entourage’s family of brands. This will also ensure the company’s proprietary genetics and cultivars are consistently available, and provides a back-up to previous product shortfalls experienced.

The supply agreement provides for …

Full story available on Benzinga.com